Mesenchymal Stem/Stromal (Mscs)-Derived Exosome Inhibits Retinoblastoma Y-79 Cell Line Proliferation and Induces Their Apoptosis Publisher



Kheradjoo H¹ ; Nouralishahi A^{2, 3} ; Firozabdi MSH⁴ ; Mohammadzadehsaliani S⁵
Source: Nanomedicine Research Journal Published:2022

Abstract

Objective(s): Based on the literature, mesenchymal stem/stromal cell-derived exosome has a dual role in tumor therapy or progress. We evaluated the possible anti-tumor effect of the MSCs-exosome on retinoblastoma Y-79 cell cells in vitro. Methods: To verify the efficient isolation of exosomes, the MSCs-exosome structure and the expression of CD9 and CD81 were examined using transmission electron microscopy (TEM) and western blotting, respectively. Y-79 cell proliferation and apoptosis were evaluated using MTT assay and flow cytometry. The Real-time PCR estimated the expression levels of Bcl-2 and microRNA-143. Results: MSCs-exosome inhibited Y-79 cell proliferation as shown by MTT assay results. Also, MSCs-exosome induced apoptosis in Y-79 cells within 72 hours of treatment. Real-time PCR results also showed that exosome therapy decreased Bcl-2 expression while up-regulating microRNA-143 expression. Conclusions: MSCs-derived exosomes could deter retinoblastoma Y-79 cells tumorigenicity, thereby providing a novel modality to manage retinoblastoma patients. © Nanomedicine Research Journal 2022. All rights reserved.